ANIX News and Press, Anixa Biosciences Inc.

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast PR Newswire SAN JOSE, Calif. , March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention...

Blend Labs Inc. Class A (BLND) is expected to report $-0.02 for Q4 2025 United Natural Foods Inc. (UNFI) is expected to report $0.51 for Q2 2026 Consumer Portfolio Services Inc. (CPSS) is expected to report $0.23 for Q4 2025 Westrock Coffee Company (WEST) is expected to report $-0.1 f...

Anixa Biosciences Inc. (ANIX) is expected to report $-0.09 for Q1 2026

2026-03-09 09:32:39 ET More on Anixa Biosciences Anixa Biosciences falls on phase 1 data for breast cancer vaccine Seeking Alpha’s Quant Rating on Anixa Biosciences Historical earnings data for Anixa Biosciences Financial information for Anixa Bioscien...

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology PR Newswire Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform Expands global intel...

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress PR Newswire Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cance...

2026-02-25 13:45:00 ET Anixa Biosciences, Inc. (NASDAQ: ANIX) , a biotechnology company focused on the treatment and prevention of cancer, announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology at Duke University School of Medicine and co-inventor of Anix...

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat ...

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation PR Newswire Multiple patients substantially exceed expected survival at low dose levels; absence of dose- limiting toxiciti...

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization PR Newswire SAN JOSE, Calif. , Feb. 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company...